Asherman's syndrome medical therapy

Jump to navigation Jump to search

Asherman's syndrome Microchapters


Patient Information


Historical Perspective




Differentiating Asherman's syndrome from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Asherman's syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Asherman's syndrome medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Asherman's syndrome medical therapy

CDC on Asherman's syndrome medical therapy

Asherman's syndrome medical therapy in the news

Blogs on Asherman's syndrome medical therapy

Directions to Hospitals Treating Asherman's syndrome

Risk calculators and risk factors for Asherman's syndrome medical therapy

Editor(s)-in-Chief: Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Canan S Fornusek, Ph.D.; Associate Editor-In-Chief: Saud Khan M.D.


Medical therapy usually follows surgical removal of fibrous bands in the uterus causing the condition. Estrogen provides stimulation for endometrial proliferation. Anti-adhesive gels may also be employed to prevent recurrence.

Medical Therapy

Hormonal therapy with synthetic or conjugated estrogen is usually prescribed following surgery to stimulate endometrial growth thereby preventing the walls of the uterus from re-adhering.

Acunzo et al found a significant effect of hyaluronic acid compared to no gel barrier for prevention of new IUA after hysteroscopic adhesiolysis. However, a large study comparing intrauterine balloon, Intrauterine contraceptive device (IUCD) and hyaluronic acid gel demonstrated that the balloon and IUCD were more effective than the gel. Fertility data was not accounted for in this analysis so long term results cannot be determined. Another retrospective cohort study compared balloon, IUCD, hyaluronic acid and controls. In this study no difference between balloon and IUCD was seen, yet these two modalities were significantly more effective than hyaluronic acid.[1]

According to the literature the only specific infection that causes Ashermans Syndrome is genital tuberculosis. There is no evidence in the literature that prophylactic antibiotics can prevent secondary intrauterine infectious complications. However, antibiotics are mandatory when infection is the cause of adhesion formation.

More studies are needed to evaluate which method of treatment is most likely to have a successful outcome. Future randomized trials are needed to prove if stem cell treatment will have a clinical role in Ashermans Syndrome.


  1. Lin XN, Zhou F, Wei ML, Yang Y, Li Y, Li TC; et al. (2015). "Randomized, controlled trial comparing the efficacy of intrauterine balloon and intrauterine contraceptive device in the prevention of adhesion reformation after hysteroscopic adhesiolysis". Fertil Steril. 104 (1): 235–40. doi:10.1016/j.fertnstert.2015.04.008. PMID 25936237.

Template:WikiDoc Sources